A Phase 2a, Open-label, Randomized Study of the Safety and Preliminary Efficacy of Triple or Quadruple Combination DAAs With Ultra-short Duration Therapy in Subjects With HCV Genotype 1b Infection (YANGTZE Study)
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2019
Price : $35 *
At a glance
- Drugs Asunaprevir (Primary) ; CC 31244 (Primary) ; Daclatasvir (Primary) ; Sofosbuvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- Acronyms YANGTZE
- 12 Nov 2019 According to a Cocrystal Pharma media release, the expected completion of enrollment has been delayed a quarter due, in part, to the civil unrest and political instability in Hong Kong.
- 09 Aug 2019 According to a Cocrystal Pharma media release, interim safety results from this trial are expected in Q4 2019. Also, completion of patient enrolment and top-line results are expected in Q1 2020.
- 08 Aug 2019 Planned End Date changed from 31 Mar 2020 to 31 Dec 2020.